Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2021 | Treating BRCA1 and BRCA2 breast cancer

Mehmet A. Sendur, MD, Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey, discusses the treatment of BRCA1 and BRCA2 mutated metastatic breast cancer using PARP inhibitors, as well as commenting on the use of sacituzumab govetican for treatment of triple-negative breast cancer. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.